Cargando…

Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression

OBJECTIVE: The understanding of systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis remains incomplete. This review assessed LN development in SLE, within-LN progression and progression to end-stage renal disease (ESRD). METHODS: A keyword-based literature search was conducted,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahajan, Anadi, Amelio, Justyna, Gairy, Kerry, Kaur, Gavneet, Levy, Roger A, Roth, David, Bass, Damon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425376/
https://www.ncbi.nlm.nih.gov/pubmed/32571142
http://dx.doi.org/10.1177/0961203320932219
_version_ 1783570482906267648
author Mahajan, Anadi
Amelio, Justyna
Gairy, Kerry
Kaur, Gavneet
Levy, Roger A
Roth, David
Bass, Damon
author_facet Mahajan, Anadi
Amelio, Justyna
Gairy, Kerry
Kaur, Gavneet
Levy, Roger A
Roth, David
Bass, Damon
author_sort Mahajan, Anadi
collection PubMed
description OBJECTIVE: The understanding of systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis remains incomplete. This review assessed LN development in SLE, within-LN progression and progression to end-stage renal disease (ESRD). METHODS: A keyword-based literature search was conducted, and 26 publications were included. RESULTS: Overall, 7–31% of patients had LN at SLE diagnosis; 31–48% developed LN after SLE diagnosis, most within 5 years. Class IV was the most commonly found LN class and had the worst prognosis. Histological transformation occurred in 40–76% of patients, more frequently from non-proliferative rather than proliferative lesions. Cumulative 5- and 10-year ESRD incidences in patients with SLE were 3% and 4%, respectively, and 3–11% and 6–19%, respectively, in patients with SLE and LN. CONCLUSIONS: Elevated serum creatinine was identified as a predictor of worsening disease state, and progression within LN classes and from SLE/LN to ESRD. This review highlights the substantial risk for developing LN and progressing to ESRD amongst patients with SLE.
format Online
Article
Text
id pubmed-7425376
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74253762020-09-04 Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression Mahajan, Anadi Amelio, Justyna Gairy, Kerry Kaur, Gavneet Levy, Roger A Roth, David Bass, Damon Lupus Review OBJECTIVE: The understanding of systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis remains incomplete. This review assessed LN development in SLE, within-LN progression and progression to end-stage renal disease (ESRD). METHODS: A keyword-based literature search was conducted, and 26 publications were included. RESULTS: Overall, 7–31% of patients had LN at SLE diagnosis; 31–48% developed LN after SLE diagnosis, most within 5 years. Class IV was the most commonly found LN class and had the worst prognosis. Histological transformation occurred in 40–76% of patients, more frequently from non-proliferative rather than proliferative lesions. Cumulative 5- and 10-year ESRD incidences in patients with SLE were 3% and 4%, respectively, and 3–11% and 6–19%, respectively, in patients with SLE and LN. CONCLUSIONS: Elevated serum creatinine was identified as a predictor of worsening disease state, and progression within LN classes and from SLE/LN to ESRD. This review highlights the substantial risk for developing LN and progressing to ESRD amongst patients with SLE. SAGE Publications 2020-06-22 2020-08 /pmc/articles/PMC7425376/ /pubmed/32571142 http://dx.doi.org/10.1177/0961203320932219 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Mahajan, Anadi
Amelio, Justyna
Gairy, Kerry
Kaur, Gavneet
Levy, Roger A
Roth, David
Bass, Damon
Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
title Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
title_full Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
title_fullStr Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
title_full_unstemmed Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
title_short Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
title_sort systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425376/
https://www.ncbi.nlm.nih.gov/pubmed/32571142
http://dx.doi.org/10.1177/0961203320932219
work_keys_str_mv AT mahajananadi systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression
AT ameliojustyna systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression
AT gairykerry systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression
AT kaurgavneet systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression
AT levyrogera systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression
AT rothdavid systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression
AT bassdamon systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression